Changes in the plasma abnormal prothrombin level following treatment of hepatocellular carcinoma
β Scribed by Mitsuo Kusano; Masami Nakanishi; Takashi Matsushima; Shin-ichi Sakamoto; Chihiro Sekiya; Yoshie Une; Mitsuo Suga; Akio Kawamura; Kazumitsu Koito; Yoichi Uekita; Junji Fujisawa; Michio Mito
- Publisher
- Springer
- Year
- 1992
- Tongue
- English
- Weight
- 305 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## BACKGROUND. Des-β₯-carboxy prothrombin (DCP) is an established marker for hepatocellular carcinoma (HCC), but the conventional enzyme immunoassay (EIA) kit lacks adequate sensitivity. Thus, a revised EIA kit with increased sensitivity has been developed. In this kit, the sensitivity has increased
Despite the increase in laser therapy, concern remains that sublethal treatment of pre-malignant lesions may adversely affect the biological behaviour of surviving cells. Integrin receptors mediate interaction of cells with the extracellular matrix and their occupation leads to focal adhesion kinase